[1]

HOU Qiong, LIU Fei, CHEN Chuanrong. Immunotherapy combined with anti-angiogenic drugs and chemotherapy in negative driver gene and advanced non-small cell lung cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(7): 775-779.

[2]

WANG Lin, LI Chongyang, LI Shuaihu, GAO Shenghan, XU Tian, LI Fei. Research progress on pathogenic fusion gene in lung cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(8): 877-885.

[3]

CUI Hua, YAN Hongxia, YIN Mei. Effects of down-regulating lncRNA LINC00176 on cisplatin resistance and autophagy in lung cancer A549/DDP cells [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(6): 616-623.

[4]

XIE Rongrong, CHEN Zhi, YANG Yu, XIE Raoying, LI Pingping, SUN Shuangshuang, CHEN Wenjun. Treatment strategies of FGFR molecular alterations in lung squamous cell carcinoma [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(2): 196-203.

[5]

PEI Qinghua, SUN Jianli. Research progress of Osimertinib acquired resistance [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(1): 105-112.

[6]

YANG Ke, LI Junling, DU Bin, TIAN Zhongqiu, JING Xiujuan. Single-arm,one-center, exploratory clinical trial of albumin-bound paclitaxel second and more line therapy for advanced non-small cell lung cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(11): 1281-1286.

[7]

PAN Huan, ZHOU Yuling, QI Weibo, SHEN Hui, JIN Jing, SHEN Jianfen, MA Xingjie, XU Yufen. Expression and function of transmembrane protein 106A in lung cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(5): 529-534.

[8]

WANG Haili, GONG Tianxiao, ZHOU Shixia, MEI Jiazhuan, ZHANG Zhongmian. Efficacy and safety of third-line treatment with mesylate apatinib in patients with advanced non-small cell lung cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(5): 567-572.

[9]

YUAN Jing, SUN Jingxue, HUANG Daiqiang, YUAN Lin, DING Dengfeng. Effects of low dose dexmedetomidine combined with ulinastatin on immune function and stress response in patients with lung cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(1): 83-88.

[10]

WANG Haixia, LIU Xingan, HOU Jiyuan, GONG Zhe, SHAN Guoyong. Influence of genetic variation of KDR on clinical outcomes of advanced NSCLC treated by first line bevacizumab regimens [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(7): 802-808.

[11]

ZHENG Qingxiu，XU Xiaoxiao，LIU Gang，MA Xiaodong. Effects of Buyanghuanwu decoction on blood hypercoagulability in lung cancer patients with Qi deficiency and blood stasis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(6): 694-699.

[12]

LI Weiwen, LI Yuan, SUN Lei, HUANG Gongcai, ZHAO Zhongwei. Synergistic effect of Addie injection on pemetrexed combined with nedaplatin in the treatment of advanced non-small cell lung cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(3): 325-328.

[13]

[14]

GAO Zhongyuan, SUN Geng, LI Min, CHEN Xi, LI Ping, WANG Xuerong. Naringin inhibits the growth of non-small cell lung carcinoma cells through down-regulating p70S6K [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(7): 762-766.

[15]

LI Su-xia, YANG Xiao-lei, CHEN Su-xiu, LIU Jie-fan, QUAN Shi-chao. Efficacy and safety of gefitinib treated elded-patients with advanced non-small cell lung cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2013, 18(12): 1410-1413.

PDF (PC)

Knowledge